Pamela J Burgess

Array ( [id] => 18575496 [patent_doc_number] => 11732010 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-22 [patent_title] => Trimer stabilizing HIV envelope protein mutations [patent_app_type] => utility [patent_app_number] => 17/181024 [patent_app_country] => US [patent_app_date] => 2021-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 30 [patent_no_of_words] => 30731 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198710 [patent_doc_number] => 20210338804 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => Vaccine Compositions For Preventing Coronavirus Disease [patent_app_type] => utility [patent_app_number] => 17/180147 [patent_app_country] => US [patent_app_date] => 2021-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42698 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180147 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885451 [patent_doc_number] => 20210171646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => Methods of Treating Cytokine Storm Infections, Including COVID-19, By Inhibiting CCR5/CCL5 (RANTES) Interaction, and Compositions for Practicing the Same [patent_app_type] => utility [patent_app_number] => 17/176657 [patent_app_country] => US [patent_app_date] => 2021-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -91 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17176657 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16915825 [patent_doc_number] => 20210188917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => NUCLEIC ACIDS ENCODING ZIKA VIRUS-LIKE PARTICLES AND THEIR USE IN ZIKA VIRUS VACCINES AND DIAGNOSTIC ASSAYS [patent_app_type] => utility [patent_app_number] => 17/168889 [patent_app_country] => US [patent_app_date] => 2021-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17168889 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17007099 [patent_doc_number] => 20210238260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => GENE THERAPY FOR HEMOPHILIA B WITH A CHIMERIC AAV CAPSID VECTOR ENCODING MODIFIED FACTOR IX POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/161602 [patent_app_country] => US [patent_app_date] => 2021-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 135711 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 217 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17161602 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17005407 [patent_doc_number] => 20210236568 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => COMPOSITIONS AND METHODS FOR THERAPY WITH DENGUE VIRUS [patent_app_type] => utility [patent_app_number] => 17/130349 [patent_app_country] => US [patent_app_date] => 2020-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130349 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16913956 [patent_doc_number] => 20210187048 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-24 [patent_title] => ONCOLYTIC RHABDOVIRUS [patent_app_type] => utility [patent_app_number] => 17/114432 [patent_app_country] => US [patent_app_date] => 2020-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31716 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17114432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18341282 [patent_doc_number] => 11638751 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-02 [patent_title] => Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity [patent_app_type] => utility [patent_app_number] => 17/106928 [patent_app_country] => US [patent_app_date] => 2020-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 22 [patent_no_of_words] => 14191 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17106928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16686815 [patent_doc_number] => 20210069290 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => Treatment of Inflammation, Autoimmune, and Neurodegenerative Disorders with Immunosuppressive Tat Derivative Polypeptides [patent_app_type] => utility [patent_app_number] => 16/951811 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16951811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16807868 [patent_doc_number] => 20210130421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => DUAL-AAV VECTOR-BASED SYSTEMS AND METHODS FOR DELIVERING OVERSIZED GENES TO MAMMALIAN CELLS [patent_app_type] => utility [patent_app_number] => 16/952016 [patent_app_country] => US [patent_app_date] => 2020-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21994 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16952016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16837949 [patent_doc_number] => 20210145961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => DOSAGE REGIMENS FOR VACCINES [patent_app_type] => utility [patent_app_number] => 17/096397 [patent_app_country] => US [patent_app_date] => 2020-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15142 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17096397 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18869839 [patent_doc_number] => 11857619 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-02 [patent_title] => Multimodal chromatography method for the purification of HIV-1 envelope glycoprotein [patent_app_type] => utility [patent_app_number] => 17/091296 [patent_app_country] => US [patent_app_date] => 2020-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 6 [patent_no_of_words] => 12592 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17091296 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16598056 [patent_doc_number] => 20210024587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-28 [patent_title] => ONCOLYTIC ADENOVIRUS COMPOSITIONS WITH ENHANCED REPLICATION PROPERTIES [patent_app_type] => utility [patent_app_number] => 17/067496 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20942 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17236620 [patent_doc_number] => 11180491 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-11-23 [patent_title] => Method of treating COVID-19 by administering the CCR5/CCL5 (RANTES) interaction inhibitor maraviroc [patent_app_type] => utility [patent_app_number] => 17/067191 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11054 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067191 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570657 [patent_doc_number] => 20210009663 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/034840 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034840 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19311850 [patent_doc_number] => 12037653 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Multiplex RT-PCR method and kit for the detection of multiple viruses of the Coronaviridae family: SARS-CoV2, SARS-CoV, HCoV, and MERS-CoV [patent_app_type] => utility [patent_app_number] => 17/034407 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 20 [patent_no_of_words] => 6980 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 231 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17034407 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16612231 [patent_doc_number] => 20210030884 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-04 [patent_title] => Novel Scaffolded HIV-1 Vaccine Immunogens [patent_app_type] => utility [patent_app_number] => 17/021821 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15714 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17021821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16541285 [patent_doc_number] => 20200407698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES [patent_app_type] => utility [patent_app_number] => 17/021163 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13444 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17021163 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16749954 [patent_doc_number] => 20210101963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => HIV ANTIBODY COMPOSITIONS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/010755 [patent_app_country] => US [patent_app_date] => 2020-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39092 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17010755 [rel_patent_id] =>[rel_patent_doc_number] =>)